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Introduction Oxymetazoline, [6-tert-butyl-3-(2-imidazolin-2-ylmethyl)-2,4-dimethylphenol], Fig. 1 , is a vasoconstrictor that acts directly on nasal membranes and has been available as a nonprescription intranasal drug in the United States for more than 40 years, approved for the relief of nasal congestion due to common colds and allergic rhinitis. Excessive doses of nonprescription oxymetazoline nasal products have been associated with cardiovascular and/or central nervous system adverse events, indicating systemic absorption from the nasal mucosa (Glazener et al., 1983; Soderman et al., 1984; Thrush, 1995) , but with no reports so far of serious toxicity. The intranasal route of drug administration provides direct access by drugs to the systemic circulation, prompting a rapid onset of action and absorption while avoiding gastrointestinal first-pass metabolism usually at a fraction of the oral dose, thus allowing a drug to undergo hepatic metabolism before elimination (Bommer, 2006) .
No human metabolism, pharmacokinetic or toxicological data have been reported for oxymetazoline so far. An in vitro phase II O-glucuronide metabolite catalyzed by UGT1A9 has been identified by LC/MS/MS in human liver microsomes and has been characterized by 1D and 2D NMR (Mahajan et al., 2010) .
In the years since the USFDA approval of oxymetazoline, both the pharmaceutical industry and the USFDA have become increasingly aware of the formation and identification of reactive drug metabolites due to their potential to elicit tissue injury. Researchers have identified numerous functional groups on drugs that can be bioactivated to reactive intermediates (Kalgutkar et al., 2005) , including p-alkyl substituted phenols as found in oxymetazoline (Bolton et al., 1990; Thompson et al., 1990; Thompson et al., 1992; Thompson et al., 1995; Yan et al., 2005) . The p-alkyl phenolic structure of oxymetazoline suggests that it might be bioactivated to This article has not been copyedited and formatted. The final version may differ from this version. (Bolton et al., 1990; Thompson et al., 1990; Thompson et al., 1992; Thompson et al., 1995; Monks and Jones, 2002; Yan et al., 2005) and a reactive metabolite of troglitazone (Kassahun et al., 2001) .
In light of these concerns, the objective of the current study was to investigate the in vitro metabolism of oxymetazoline, including its bioactivation potential, using human, rat and rabbit liver S9 fractions and their microsomes; to identify the formation of a reactive species by trapping it with nucleophiles such as glutathione and N-acetylcysteine; to characterize the glutathione conjugate of oxymetazoline by 1D-and 2D NMR in order to identify the putative reactive intermediate; and to identify the specific human P450 isoforms involved in the oxidation of oxymetazoline. The identification of the glutathione conjugates of oxymetazoline demonstrates its tendency to form a p-quinone methide intermediate (Thompson et al., 1995) .
This article has not been copyedited and formatted. The final version may differ from this version. Trapping Reactive Metabolites of Oxymetazoline with Glutathione or N-AcetylcysteineSupplemented S9 Fractions. A 10 µL aliquot of 50 µM oxymetazoline was added to 250 µL of liver S9 fractions (5 mg protein/mL) of various species with the same conditions as those used in the liver S9 fraction incubations, except that the incubation medium was supplemented with 100 µL of 2 mM glutathione as a trapping agent. The trapping experiments with N-acetylcysteine and rabbit liver S9 fractions were performed in an analogous manner, substituting 100 µL of 3 mM N-acetylcysteine for glutathione. Control reactions omitting drug, protein, NADPH, or trapping agent were incubated simultaneously and analyses of the conjugates formed was performed using the LC/MS/MS method described for the S9 fractions.
Biosynthesis and NMR Identification of Oxymetazoline-Glutathione Conjugate. A 50 µL aliquot of 100 µM oxymetazoline and 2500 µL of rabbit liver S9 fraction (10 mg protein/mL) were added to 1450 µL of 0.1 M potassium phosphate buffer (pH 7.4) containing 3 mM magnesium chloride. Tubes containing the reaction mixtures were pre-incubated for 3 min at 37°C and reactions were initiated by addition of 500 µL aliquots each of 4 mM NADPH and 4 mM glutathione. The resulting solutions were incubated for 3 h at 37°C and were processed similarly to the liver S9 fractions. The dried supernatants were reconstituted in mobile phase and 100 µL aliquots were injected into the HPLC and analyzed with the same LC mobile phase gradient as that used with the S9 fractions. The semi-purified fractions containing the glutathione conjugate were collected between 4.0 and 5.0 min with a time-based fraction collection system. The semi-purified collected fractions were pooled, dried in the Turbo Vap ® LV drier at room temperature, reconstituted with 2 mL of mobile phase and re-injected into the Table 1 ).
Results

Identification of
The product ion at m/z 177 resulted from cleavage of the methylimidazole moiety, indicating that the aromatic moiety was unchanged and that the imidazoline ring had been dehydrogenated to an imidazole group. The appearance of a product ion at m/z 81 resulted from cleavage of the methylimidazole moiety. Furthermore, the product ions at m/z 241 and 203 were two hydrogen atoms less than the corresponding ions at m/z 243 and 205 of oxymetazoline, indicating the loss of water (18 amu) and of the t-butyl group (56 amu), respectively. From these results, we
propose that the imidazoline ring was metabolized to a putative hydroxyimidazoline intermediate which then spontaneously eliminated water to the more stable imidazole ring (Acheampong et al., 1996; He et al., 2000) . (Mutlib et al., 2000; Chen et al., 2002; Mutlib et al., 2002) . The proposed fragmentation pattern of M6 is shown in Fig. 6A . The major product ion at m/z 437 resulted from the loss of pyroglutamic acid (129 amu) from the [M+H] + ion at m/z 566, indicative of a glutathione moiety (Mutlib et al., 2000; Chen et al., 2002; Mutlib et al., 2002) . The loss of water (18 amu m/z 259, confirming M8 to be the cysteine conjugate of oxymetazoline, which results from the dipeptidase hydrolysis of the glutathione conjugate (Mutlib et al., 1999 (Thompson et al., 1995) ( Fig. 7) .
When Although the 2D-ROESY spectrum of oxymetazoline exhibited several cross peak interactions, we identified a strong key cross peak interaction between the H B protons of the 4-methyl group of oxymetazoline at 2.107 ppm and the single aromatic proton (H F ) at 6.898 ppm, which could further determine that glutathione had been conjugated with the 4-methyl group of oxymetazoline. The bridge methylene protons (H E ) exhibited cross peak interactions with both the 2-methyl and 4-methyl protons of oxymetazoline, and thus were not distinctive. As predicted, a characteristic cross peak interaction was observed between the methylene protons of the 4-S-benzyl group (H B ) at 3.689 ppm and the aromatic H F proton at 6.918 ppm of M6 (Fig. 9) .
Therefore, 1 H-NMR data indicating the deshielding effect of a sulfur atom on the chemical shift differences between H B and H C protons and differences in the proton integration of these same protons, as well as the 2D-ROESY data plot which demonstrated cross peak interactions between H B and H F , together indicated that the glutathionyl moiety was conjugated with the 4-methyl group (Fig. 9) . Furthermore, 1,4-quinone methides are more electrophilic than 1,2-quinone methides (Bolton and Thompson 1991; Bolton et al., 1992; Krol and Bolton, 1997) . 
Identification of the
Discussion
The metabolic disposition of oxymetazoline in humans had not previously been studied. In this study, we have examined the in vitro metabolism of oxymetazoline by pooled human, rat or rabbit liver microsomes and the liver S9 fractions from these same animal species, supplemented with NADPH, in an attempt to elucidate the metabolic pathways leading to the formation of A proposed metabolic scheme for oxymetazoline in human liver S9 is shown in Fig. 3 .
The selective monohydroxylation of the t-butyl group observed with oxymetazoline had previously been observed with the food preservative BHT (Bolton et al., 1990) , with the H 1 -receptor antagonists terfenadine and ebastine (Jones et al., 1998; Hashizume et al., 2002) , and with the isopropyl group of the anti-inflammatory drug ibuprofen (Hamman et al., 1997) . The putative hydroxyimidazoline intermediate (HM A ) (Fig. 3) resulting from the hydroxylation of imidazoline ring of oxymetazoline was not detected because it would likely eliminate water to produce the resonance-stabilized imidazole metabolite (4',5'-dehydro-oxymetazoline; M2).
Similar mechanisms have been reported for the other imidazoline-containing drugs, brimonidine (Acheampong et al., 1996) and monoxidine (He et al., 2000) . On the other hand, M3 could be formed either from M2 by subsequent hydroxylation of the t-butyl group or from hydroxylation of the imidazoline ring of M1 via the putative hydroxyimidazoline intermediate (HM B ) (Fig. 3) .
The second-generation dihydroxylated metabolites resulting from monohydroxylation of the tbutyl group and monohydroxylation of one of the aromatic methyl groups to form a hydroxybenzyl metabolite were identified in the rat and rabbit liver S9 fractions, but were not observed in the human liver S9 fractions. The human and rat liver microsomes produced fewer (Thompson et al., 1995) . To confirm this bioactivation pathway, liver S9 incubations of oxymetazoline were performed in the absence of NADPH. No glutathione conjugates were detected in these incubations. As a result, the identification and This article has not been copyedited and formatted. The final version may differ from this version. (Thompson et al., 1995; Bolton et al., 1997; Monks and Jones, 2002; Yan et al., 2005 Fig. 7 . We postulate that the formation of the putative p-quinone methide involves successive one-electron oxidation steps by P450 as suggested by Koymans et al. (1993) and Thompson et al. (1995) (Bolton et al., 1990; Thompson et al., 1990; Thompson et al., 1992; Thompson et al., 1995; Monks and Jones, 2002) . Bolton et al. (1990) have observed that bulky alkyl substituents ortho to the phenolic group affected the rate of reaction of the p-quinone methide with nucleophiles, and that hindered phenols, which have o-methyl or o-t-butyl groups adjacent to the phenoxy group, help to shield the quinoid oxygen from solvent interactions, increasing the stability of the p-quinone methide and allowing time for its diffusion away from the site of formation and from interaction with vital cellular macromolecules, thus reducing its toxicity potential (Bolton et al., 1995) . In contrast, unhindered p-alkyl phenols will form reactive p-quinone methides that are more hepatotoxic and cytotoxic by the same mechanism (Bolton et al., 1995; Yan et al., 2005) . Thus, we attribute the reduction or the absence of toxicity potential of oxymetazoline to steric hindrance by the o-t-butyl and the o-methyl groups, which reduce its toxicity potential by the same mechanism (Bolton et al., 1995; Yan et al., 2005) . We did not determine whether covalent binding of the intermediate to proteins occurred and, if so, what levels of binding were reached.
In conclusion, oxymetazoline has demonstrated the likelihood to be bioactivated to a reactive intermediate species, as identified from its corresponding glutathione conjugates, in incubations with liver S9 fractions supplemented with NADPH. Consequently, a bioactivation pathway is proposed. We rationalize that this bioactivation pathway is unlikely to be a safety concern with oxymetazoline nasal products. Other factors contributing to the margin of safety are the brief intranasal dosage regimen, for a few days at low doses. Uetrecht (2001and 2008 has observed that drug-induced toxicity due to formation of reactive intermediates is seldom associated with drugs administered at doses of 10 mg or less. In addition, we have reported the 
